Indications |
Topical/Cutaneous Corticosteroid-responsive dermatoses Adult: As 0.05% cream, ointment or lotion: Apply sparingly onto the affected areas 2-4 times/day. Discontinue therapy when control is achieved. |
Contraindications |
Hypersensitivity to any of the components. Primary infective skin conditions. |
Warnings / Precautions |
Caution when using in paed patients. Evaluate periodically for evidence of HPA-axis suppression. In the event of secondary infections use appropriate antibiotics and discontinue topical steroid. Pregnancy and lactation. |
Adverse Reactions |
Burning, itching, irritation, scaling, folliculitis, hypertrichosis, contact dermatitis, skin peeling, transient erythema. |
Overdose Reactions |
Systemic absorption of topical corticosteroids can result in reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia and glucosuria. Glucocorticosteroid insufficiency may occur upon withdrawal of treatment. If HPA axis suppression is present, withdraw drug or reduce the frequency of application. Alternatively, a less potent corticosteroid may be used instead. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Supplemental systemic corticosteroids may be needed in the treatment of glucocorticosteroid insufficiency. |
Mechanism of Actions |
Desonide is a corticosteroid used mainly for its glucocorticoid activity in the treatment of various skin disorders. |
Storage Conditions |
Topical/Cutaneous: Store below 30°C. |
ATC Classification |
D07AB08 - desonide ; Belongs to the class of moderately potent (group II) corticosteroids. Used in the treatment of dermatological diseases. S01BA11 - desonide ; Belongs to the class of corticosteroids. Used in the treatment of inflammation of the eye. |
Storage |
Topical/Cutaneous: Store below 30°C. |
Available As |
|
Desonide
Post Review about Desonide Click here to cancel reply.
Desonide Containing Brands
Desonide is used in following diseases
Drug - Drug Interactions of Desonide
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.